

In the News: Congratulations to the following awardees!!



Lindsey Mattick, PhD candidate in the Department of Epidemiology and Environmental Health (EEH), is the PI and trainee on an F-31 award from the National Institute of Aging/NIH entitled, *Follicle Stimulating Hormone and Bone Loss in Postmenopausal Women*. Heather Ochs-Balcom, Associate Professor in EEH and Jean Wactawski-Wende, Professor in EEH and the SPHHP Dean, are her Faculty Sponsors. The study will explore the independent effects of estrogen and follicle stimulating hormone (FSH), which rises with menopause, on bone mineral density and fracture risk.



Jeffrey Miecznikowski, Associate Professor of Biostatistics, is Co-I on the continuation of an award from the National Institute of Dental & Craniofacial Research/NIH (PI: Abhiram Maddi, Periodontics & Endodontics) for the research project entitled, *Candida albicans glycosidases, DFG5 and DCW1, in virulence and pathogenesis*. The study will determine the functions of *DFG5* and *DCW1* in virulence and pathogenesis. Targeting *DFG5* and *DCW1* and their functions can lead to novel and efficacious antifungal drugs.



Ekaterina Noyes, Professor of Epidemiology and Environmental Health, is PI on a new award from Pharmavite for a project entitled, *Impact of deficiencies in immune nutrients on healthcare utilization in outcomes in the US*. The study will examine how micronutrient deficiencies in patients over 50 years of age affect the rates of acute infections; hospital outcomes (LOS, post discharge infections and re-admissions); and how the relationship between the immune nutrient deficiencies and healthcare utilization may vary for specific population subgroups, including patients with autoimmune diseases, cancer, and those on Medicaid.



Guan Yu, Assistant Professor of Biostatistics, is Co-I on the continuation of an award from the National Institute of Dental & Craniofacial Research/NIH (PI: Jill Kramer, Oral Biology) for the project entitled, *Analysis of MyD88-mediated Immune Activation in Sjogrens Syndrome Pathogenesis*. The study seeks to identify the tissue-specific contributions of MyD88 and the mediated signaling networks that govern pSS disease pathogenesis. Insights gained by the study will reveal novel mechanisms that govern chronic inflammation in pSS and pathways that may be targeted therapeutically in pSS and other autoimmune diseases.

Ekaterina Noyes and Guan Yu are both Co-Is on a new award from the Agency for Healthcare Research and Quality (PI: Sharon Hewner, Nursing) for the project entitled, *Implementing personalized cross-sector transitional care management to promote care continuity, reduce low value utilization, and reduce the burden of treatment for high-need, high-cost patients*. This project is to improve the evidence-based coordinating transitions intervention to include cross-sector continuity, risk stratification and social needs assessment, and shared care planning for HNHC patients. These data can then be hardwired into health information exchanges (HIE) and transmitted across settings.

In This Issue

In the News: Congratulations to the Following Awardees	1
Grant Clinic.....	3
NIH Funding Opportunities	
Request for Applications (RFA)	5
Program Announcements Reviews in an Institute (PAR)	10
Program Announcements (PA)	16
Individual Actions for Sustainability	17

GRANT CLINIC

GENERAL NOTICE

A new Research Space/Venue Questionnaire is now available on the [SPHP website](#). Investigators who are planning to submit proposals, please complete both the [RAS Questionnaire](#) and [Research Venue/Space Questionnaire](#).

NOT-OD-21-073

Upcoming Changes to the Biographical Sketch and Other Support Format Page for Due Dates on or after May 25, 2021

Please check the Notice for the Specific changes. A full copy of the updated Biosketch instructions can be found [here](#). Use of the updated format pages will be required for applications and Research Performance Progress Reports (RPPRs) submitted for due dates on or after May 25, 2021. During the transition to the new Biosketch format, NIH will not withdraw applications that include the previous Biosketch format. Beginning with applications submitted on or after January 25, 2022, failure to follow the appropriate Biosketch format may cause NIH to withdraw your application from consideration.

REQUESTS FOR PROPOSAL

NOT-AI-21-045

2021 NIAID Omnibus Broad Agency Announcement HHS-NIH-NIAID-BAA2021-1 Now Available

The Research Areas included in this NIAID DMID OMNIBUS BROAD AGENCY ANNOUNCEMENT No. HHS-NIH-NIAID-BAA2021-1 are:

DIVISION OF MICROBIOLOGY AND INFECTIOUS DISEASES (DMID), NIAID, NIH

Research Area 001: Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases.

Research Area 002: Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant (AMR) Infections and Emerging Infectious Diseases.

Research Area 003: Advanced Development of Sequencing-Based Diagnostics for Biothreats and Emerging Infectious Diseases

Proposals submitted in response to the BAA Solicitation must be received by 3:00 p.m. Eastern Time, **May 24, 2021**.

NOTICE OF CHANGES TO FUNDING OPPORTUNITIES

[NOT-DA-21-057](#)

Notice of Change to RFA-DA-21-016, "Novel Approaches to Decrease Stigma of Substance Use Disorders in order to Facilitate Prevention, Treatment, and Support During Recovery (R43/R44 - Clinical Trials Optional)"

The purpose of this notice is to inform interested applicants of a change to the Advisory Council Review date to Funding Opportunity Announcement (FOA) [RFA-DA-21-016](#), "Novel Approaches to Decrease Stigma of Substance Use Disorders in order to Facilitate Prevention, Treatment, and Support During Recovery (R43/R44 - Clinical Trials Optional)". **Part 1. Overview Information Key Dates Revised to Read: Advisory Council Review August 2021** All other aspects of this FOA remain unchanged.

[NOT-DA-22-015](#)

Notice of NIDA's Participation in NOT- MD-21-008 "Notice of Special Interest (NOSI): Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities"

The purpose of this Notice is to inform potential applicants that the National Institute on Drug Abuse ([NIDA](#)) will participate, effective immediately in [NOT-MD-21-008](#), Notice of Special Interest (NOSI): Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities".

NOTICE OF SPECIAL INTEREST

If you will be applying under any of the special interest topics listed below, please indicate so, including the NIH Notice number, in the Comments box of the RAS Questionnaire. The RAS staff will ensure that this information is included with the application to NIH.

[OT-AG-21-015](#)

Aging-Relevant Behavioral and Social Research on Coronavirus Disease 2019 (COVID-19)

This Notice of Special Interest (NOSI) is to highlight the continuing need for behavioral, psychological, social, and economic research on SARS-CoV-2 and coronavirus disease 2019 (COVID-19). There is a need for ongoing research on the longer-term effects of COVID-19 on the health and well-being of those infected, those caring for the sick, and many others whose lives were disrupted by the pandemic and its associated mitigation and prevention strategies. **Applicants must include "NOT-AG-21-015" in box 4B of the SF424 R&R form.** This NOSI will expire on May 08, 2023.

[NOT-CA-21-031](#)

Understanding the Effects of Cancer and Cancer Treatment on Aging Trajectories and Aging Outcomes

The purpose of this Notice of Special Interest is to solicit investigator-initiated applications that aim to better understand the effects of a cancer diagnosis and subsequent cancer treatment on aging trajectories and aging outcomes. Investigations in understudied populations, including those that are medically underserved, are encouraged. This notice applies to due dates on or after *March 8, 2021*, and subsequent receipt dates through January 7, 2024. **Applicants must include "NOT-CA-21-031" in box 4B of the SF424 R&R form.** This NOSI will expire on January 08, 2024.

[NOT-DA-21-011](#)

Effects of Smoking and Vaping on the Risk and Outcome of COVID-19 Infection

The purpose of this notice is to communicate NIDA's interest in supporting research on **the effects of smoking or vaping tobacco or marijuana on the risk of acquiring COVID-19 and the clinical course of the infection.** This Notice is a reissuance of [NOT-DA-20-084](#). Research applications focusing on individuals who smoke or vape either marijuana and/or tobacco to determine: 1) the risk of contracting a COVID-19 infection, 2) the effects on asymptomatic COVID-19 infected persons, and 3) the course of the COVID-19 infection are interested. **Applicants must include "NOT-DA-21-011" in box 4B of the SF424 R&R form.** This NOSI will expire on September 08, 2024.

[NOT-DA-21-017](#)

Medical Consequences of Smoking & Vaping Drugs of Abuse in Individuals with HIV and COVID-19

NIDA is interested in receiving research applications focusing on individuals with HIV who smoke or vape marijuana, tobacco, cocaine and/or methamphetamine to determine the long-term effects of their use among individuals with HIV and COVID-19. **Applicants must include “NOT-DA-21-017” in box 4B of the SF424 R&R form.** This NOSI will expire on September 08, 2024.

[NOT-MD-21-008](#)

Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities

The purpose of this NOSI is to solicit community-engaged research to: 1) evaluate intervention strategies (e.g., expand reach, access) to facilitate vaccination uptake in clinical and community contexts; and 2) address the barriers to increasing reach, access, and uptake of vaccinations among health disparity populations at high risk and likely to experience vaccine hesitancy. Submit applications for this initiative using [PA-20-183](#) & [PA-20-185](#). **Applicants must include “NOT-MD-21-008” in box 4B of the SF424 R&R form.** This NOSI will expire on January 08, 2022.

[NOT-TR-21-011](#)

Availability of Emergency Administrative Supplements to Clinical and Translational Science Award (CTSA) Program Awards to Address 2019 Novel Coronavirus Disease Public Health Needs

The National Center for Advancing Translational Sciences (NCATS) is issuing this notice to highlight the urgent need for projects that address the COVID-19 Public Health Emergency. The Clinical and Translational Science Award (CTSA) Program is uniquely qualified to contribute to these efforts. NCATS expects to issue 2-9 awards (anticipated to be \$30,000 to \$60,000 Direct Costs) for provision of clinical data in specified formats to support illness/infection status/surveillance determinations and/or clinical study data. Submit applications for this initiative using [PA-20-272](#). **Applicants must include “NOT-TR-21-011” in box 4B of the SF424 R&R form.** This NOSI will expire on June 02, 2021.

[NOT-CA-21-008](#)

Availability of Administrative Supplements to Adapt/Repackage Visualization Methods for Enhancing Cancer Moonshot Data

Through funds available from the [Cancer Moonshot Initiative](#), and pursuant to the National Cancer Institute's (NCI's) interest in advancing data visualization tools and methods for cancer research, applications are invited, through [PA-20-272](#) in conjunction with this Notice of Special Interest (NOSI), for one-year administrative supplements to support the adaptation and repackaging of existing broad-based visualization methods that have the potential to make Cancer Moonshot-aligned data more exploratory and interpretable by the broader cancer research community. Submit applications for this initiative using [PA-20-272](#). **Applicants must include “PA-20-272” in box 4B of the SF424 R&R form.** Applications can be submitted on a rolling basis for possible funding in FY2021, FY2022, and FY2023. This NOSI will expire on November 3, 2022.

[NOT-OD-21-087](#)

Developing and Testing Multilevel Physical Activity Interventions to Improve Health and Well-Being

The Office of Disease Prevention and participating ICOs are issuing this Notice to highlight our interest in encouraging highly innovative and promising translational research to improve our understanding of how to increase and maintain health-enhancing physical activity using multi-level interventions in a wide range of population groups across the lifespan (e.g., including racial and ethnic minorities, children, older adults, persons with medical/behavioral health conditions, and persons with disabilities). **Applicants must include “NOT-OD-21-087” in box 4B of the SF424 R&R form.** This NOSI will expire on February 16, 2024.

[NOT-OD-21-100](#)

Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health

The objective of this NOSI is to encourage research grant applications that address patient adherence to treatment and prevention regimens to promote health outcomes. Applications may address healthcare regimen initiation, implementation, and/or persistence by patients. Descriptive and intervention research may address adherence determinants at one or more levels of ecologic influence, including the patient,

caregiver/family, provider, healthcare system, and community levels. **Applicants must include** “NOT-OD-21-100” in box 4B of the SF424 R&R form. This NOSI will expire on June 08, 2024.

NIH Funding Opportunities

NIH Funding Opportunities: Request for Applications (RFA)

MAY DUE DATES

[RFA-LM-21-001](#) (T15 Clinical Trial Not Allowed)

NLM Institutional Grants for Research Training in Biomedical Informatics and Data Science

This FOA invites training grant applications for support of predoctoral and postdoctoral training for research careers in biomedical informatics and data science. Applications may be for the creation of entirely new programs or for the renewal of existing NLM training programs.

Application Due Dates: May 14, 2021

[RFA-RM-21-021](#) (U01 Clinical Trial Allowed)

[RFA-RM-21-022](#) (U01 Clinical Trial Allowed)

Transformative Research to Address Health Disparities and Advance Health Equity

The Transformative Research to Address Health Disparities and Advance Health Equity at Minority Serving Institutions initiative is soliciting applications to support collaborative investigative teams or individual scientists who propose unusually innovative research projects, which, if successful, would have a major impact in developing, implementing, or disseminating innovative and effective interventions to prevent, reduce, or eliminate health disparities and advance health equity. No preliminary data are required. Projects must clearly demonstrate.

Application Due Dates: May 28, 2021

JUNE DUE DATES

[RFA-DK-20-034](#) (U24 Clinical Trial Optional)

Program to Advance the Career Development of Scientists from Diverse Backgrounds Conducting Nutrition, Obesity, Diabetes, and Related Research

The purpose of this Funding Opportunity Announcement is to enhance the diversity of the research workforce who are available to successfully compete for independent research funding from NIH in the areas of nutrition, obesity, diabetes, and related conditions. This program will establish a consortium providing professional development, mentoring, networking, pilot and feasibility funds, and other opportunities designed to advance the career development of post-doctoral scholars and early career faculty from diverse backgrounds, including those from groups nationally underrepresented in biomedical and behavioral research, who intend to pursue a research career focused on nutrition, obesity, diabetes, and/or related conditions.

Application Due Dates: June 17, 2021

[RFA-AG-22-013](#) (R24 Clinical Trial Optional)

High-Priority Behavioral and Social Research Networks

This FOA invites applications to develop new research and research infrastructure for life course research on aging; attract new researchers in aging; infuse a focus on health disparities into aging research; and address ongoing needs for harmonization and biomarker collection in large population panel studies, as recommended by the [2019 BSR NACA Review](#).

Application Due Dates: June 23, 2021

JULY DUE DATES

[RFA-TW-21-001](#) (Collaborative U01 Clinical Trial Optional)

[RFA-TW-21-002](#) (Collaborative U2R Clinical Trial Optional)

Hubs of Interdisciplinary Research and Training in Global Environmental and Occupational Health (GEOHealth)

This FOA solicits applications for research training activities in linked Hubs of Interdisciplinary Research and Training in Global Environmental and Occupational Health (GEOHealth). The overall objective of the GEOHealth program is to support the development of institutions in the Low- or Middle-Income Countries (LMICs) that will serve as regional hubs for collaborative research, data management, research training, curricula and outreach material development, and policy support around high priority local, national, and regional environmental and occupational health threats.

Application Due Dates: July 8, 2021

[RFA-AI-21-025](#) (R01 Clinical Trial Optional)

Prevention Strategies to End the HIV Epidemic

The purpose of this FOA is to support projects to improve use of evidence-based HIV prevention interventions among populations in priority areas identified as highly impacted by HIV. Research funded under this FOA will support the goals of the DIAGNOSE and PREVENT pillars of the *Ending the HIV Epidemic: A Plan for America* (EHE) initiative towards reducing HIV incidence. Creative, multidisciplinary approaches are needed to meet the needs of specific populations and localities. **Application Due Dates:** July 30, 2021

AUGUST DUE DATES

[RFA-MD-21-004](#) (R01 Clinical Trial Optional)

Understanding and Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities

This initiative will support (1) observational research to understand the role of structural racism and discrimination (SRD) in causing and sustaining health disparities, and (2) intervention research that addresses SRD in order to improve minority health or reduce health disparities.

Application Due Dates: August 24, 2021

[RFA-AI-21-024](#) (R01 Clinical Trial Optional)

Multidisciplinary Treatment Approaches to End the HIV Epidemic

The purpose of this Funding Opportunity Announcement (FOA) is to utilize implementation science to develop, implement, and evaluate creative, multidisciplinary approaches to healthcare delivery that more effectively engage and retain individuals in HIV care and treatment so that they achieve durable viral suppression. Research funded under this FOA will support the goals of the DIAGNOSE and TREAT pillars of the *Ending the HIV Epidemic: A Plan for America* (EHE) initiative by seeking to achieve more rapid and sustained viral suppression and improved outcomes for people with HIV through better healthcare engagement.

Application Due Dates: August 05, 2021

SEPTEMBER DUE DATES

[RFA-AG-22-016](#) (R61/R33 Clinical Trial Required)

Mechanism-Focused Research to Promote Adherence to Healthful Behaviors to Prevent Mild Cognitive Impairment (MCI) and Alzheimer's Disease and Related Dementias (AD/ADRD)

This FOA will support pilot research (R61) to identify, measure, and assess the malleability of psychological or interpersonal adherence-relevant targets that, if successful, can transition to an R33 phase for implementation of rigorous, proof-of-concept intervention studies. The transition from the R61 to the R33 phase of the award will be administratively reviewed for and be dependent upon successful completion of the go/no-go criteria specified for the R61 phase.

Application Due Dates: September 05, 2021

**[RFA-RM-21-015](#) (DP1 Clinical Trial Optional)
NIH Director's Pioneer Award Program**

The NIH Director's Pioneer Award Program supports individual scientists of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. To be considered pioneering, the proposed research must reflect substantially different scientific directions from those already being pursued in the investigator's research program or elsewhere.

Application Due Dates: September 10, 2021

OCTOBER DUE DATES

[RFA-AG-22-009](#) (R25 Clinical Trial Not Allowed)

[RFA-AG-22-010](#) (R25 Clinical Trial Not Allowed)

Short Courses on Interdisciplinary Behavioral and Social Sciences Research on Alzheimer's Disease and Related Dementias

The goal of the FOA is to support short courses geared towards advancing selected priority topic areas identified by the NIH on Aging in order to advance behavioral and social science research on Alzheimer's disease and its related dementias (AD/ADRD). It targets the following three priority research areas: 1) cross-national dementia research using harmonized data on cognitive function; 2) behavioral economic approaches to improve AD/ADRD health care delivery at the organizational level; and 3) integrating machine learning and the social sciences to improve healthcare research in AD/ADRD.

Application Due Dates: October 4, 2021

[RFA-HL-21-014](#) (R01 Clinical Trial Optional)

Understanding and Reducing Cardiovascular Disease in Type 1 Diabetes Mellitus

This funding opportunity will support epidemiologic studies to refine risk assessment, mechanistic trials to enhance understanding of the pathophysiology of CVD in T1DM, and small clinical trials that could inform the future development of larger trials focused on preventing or reducing the CVD complications of T1DM. The overall goal is to develop evidence-based guidelines to prevent or reduce CVD complications of T1DM across the lifespan.

Application Due Dates: October 15, 2021

[RFA-DK-21-015](#) (P30 Clinical Trial Optional)

Nutrition Obesity Research Centers

This FOA invites applications from institutions/organizations that propose to establish core centers that are part of an integrated and existing program of nutrition and/or obesity research. The Nutrition Obesity Research Centers (NORC) program is designed to support and enhance the national research effort in nutrition and obesity. NORCs support three primary research-related activities: Research Core services, a Pilot and Feasibility (P and F) program, and an Enrichment program. All activities pursued by Nutrition Obesity Research Centers are designed to enhance the efficiency, productivity, effectiveness, and multidisciplinary nature of research in nutrition and obesity.

Application Due Dates: October 20, 2021

NOVEMBER DUE DATES

[RFA-AA-21-005](#) (P50 Clinical Trial Optional)

Specialized Alcohol Research Centers

The overall purpose of the NIAAA Alcohol Research Center program is to provide leadership in conducting and fostering interdisciplinary, collaborative research on a wide variety of topics relevant to the Institute's mission. These topics include, but are not limited to: the nature, etiology, genetics, diagnosis, treatment, and prevention of alcohol use disorder, alcohol-related end organ diseases and their biomedical, psychosocial, and economic consequences across the lifespan and racial/ethnic groups and other health disparity populations. **Application Due Dates:** November 15, 2021

**[RFA-AA-21-006 \(P60 Clinical trial Optional\)](#)
Comprehensive Alcohol Research Centers**

The overall purpose of the NIAAA Alcohol Research Center program is to provide leadership in conducting and fostering interdisciplinary, collaborative research on a wide variety of topics relevant to the Institute's mission. These topics include, but are not limited to: the nature, etiology, genetics, diagnosis, treatment, and prevention of alcohol use disorder, alcohol-related end organ diseases and their biomedical, psychosocial, and economic consequences across the lifespan and racial/ethnic groups and other health disparity populations. **Application Due Dates:** November 15, 2021

MULTIPLE DUE DATES

**[RFA-NS-20-008 \(R41/R42\)](#); [RFA-NS-20-010 \(R43/R44\)](#) clinical trial required
[RFA-NS-20-009 \(R41/R42\)](#); [RFA-NS-20-011 \(R43/R44\)](#) clinical trial not allowed**

HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management

These FOAs aim to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management. They are focused on applications directed at improving pain treatment, including the development of new non-addictive medications and devices and objective pain measurement. In addition, NIH is interested in new screening tools and models focused specifically on pain and development of pain therapies. **Application Due Dates:** September 8, 2021, January 6, 2022, April 6, 2022, and September 8, 2022

[RFA-AG-21-021](#) K76 Clinical Trial Required

Paul B. Beeson Emerging Leaders Career Development Award in Aging

This FOA invites early-stage physician and other health professional investigators with a commitment to aging and/or aging-related diseases to apply for this award to advance their research and leadership skills in their specialty and in the broader field of aging and geriatrics research. LOI due 30 days before application due date.

Application Due Dates: October 22, 2021 and October 21, 2022

**[RFA-NS-19-043 \(K99/R00\)](#) clinical trial not allowed
[RFA-NS-19-044 \(K99/R00\)](#) independent clinical trial required**

BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity

This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The BRAIN Initiative is aimed at revolutionizing our understanding of the human brain. By accelerating the development and application of innovative technologies, researchers will be able to produce a new dynamic picture of the brain that, for the first time, will show how individual cells and complex neural circuits interact in both time and space.

Application Due Dates: June 9, 2021; October 6, 2021; February 10, 2022; June 8, 2022; October 11, 2022

**[RFA-OD-20-008 \(K01\)](#) clinical trial not allowed
[RFA-OD-20-011 \(K01\)](#) clinical trial required**

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research

This award provides support and protected time (2-5 years) for an intensive, supervised career development experience in biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing and that will lead to research independence. Candidates for the K01 award must have a research or health-professional doctoral degree.

Application Due Dates: October 08, 2021, July 8, 2022

**[RFA-OD-20-009 \(K99/R00\)](#) clinical trial not allowed
[RFA-OD-20-010 \(K99/R00\)](#) clinical trial required**

Pathway to Independence Award in Tobacco Regulatory Research

This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. This program will provide independent research support during this transition in order to help awardees launch competitive, independent research careers.

Application Due Dates: October 08, 2021, July 8, 2022

[RFA-DA-19-019 \(R43/R44\)](#) clinical trial optional

[RFA-DA-19-020 \(R41/R42\)](#) clinical trial optional

America's Startups and Small Businesses Build Technologies to Stop the Opioid Crisis

These FOAs invite applications from US small business concerns to develop technologies to provide science-and research-based solutions to the opioid emergency. **Application Due Dates:** September 8, 2022

[RFA-ES-19-011 \(R21\)](#) – clinical trial not allowed

Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences

This FOA supports novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data. A distinguishing feature of an appropriate study is the need for rapid review and funding, substantially shorter than the typical NIH grant review/award cycle, for the research question to be addressed and swiftly implemented. **Application Due Dates:** Monthly due dates; please refer to the RFA.

[RFA-CA-21-013](#) (R21 Clinical Trial Optional)

[RFA-CA-21-014](#) (U01 Clinical Trial Optional)

[RFA-CA-21-015](#) (U24 Clinical Trial Optional)

[RFA-CA-21-016](#) (U24 Clinical Trial Optional)

Early-Stage Development of Informatics Technologies for Cancer Research and Management

The purpose of FOA is to invite applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. This FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined as initial tool development or the significant modification of existing tools for new applications.

Application Due Dates: June 8, 2021; November 17, 2021

[RFA-DK-20-032](#) (R34 Clinical Trial Required)

Pilot and Feasibility Studies to Facilitate the Use of Diabetes Self-Management Education and Support to Improve Diabetes Care

The FOA is to test an innovative and pragmatic approach to address barriers to and facilitate greater use of diabetes self-management education and support (DSMES) by people living with diabetes mellitus. Research applications should engage key stakeholders in cultivating a practical and sustainable strategy with the potential for dissemination. The pilot trial of the proposed strategy should be designed to generate preliminary data in support of a future, full-scale trial to study broader dissemination and implementation to expand the use of DSMES.

Application Due Dates: June 22, 2021; June 22, 2022; June 22, 2023.

[RFA-AI-21-023](#) (R01 Clinical Trial Optional)

RESPOND: Epidemiology to End the HIV Epidemic (RESPOND: EEE)

The purpose of FOA is to support applications that address the RESPOND pillar of the *Ending the HIV Epidemic: A Plan for America* (EHE) initiative. The objective is to better understand HIV susceptibility and ongoing transmission in the United States (U.S.) using local and population-level epidemiology in collaboration with implementing partners. Data generated through this research will inform intervention approaches and facilitate more timely evaluation of context-specific HIV control strategies towards the goal of ending the HIV epidemic in the U.S.

Application Receipt Dates: Multiple dates, see announcement.

NIH Funding Opportunities: Program Announcements Reviews in an Institute (PAR)

[PAR-20-236\(R25\)](#) Clinical Trials Not Allowed

Providing Research Education Experiences to Enhance Diversity in the Next Generation of Substance Use and Addiction Scientists

This FOA invites applications from established researchers with a record of NIH funding, who can demonstrate that they have successfully guided previous early career scientists to independent research careers and are able to direct an educational research capacity building program. This R25 program intends to strengthen the pipeline of individuals in biomedical, behavioral, and clinical substance use and addiction research across various stages of the research pipeline to enhance the number of independently funded investigators from diverse backgrounds. **Application Due Dates:** August 10, 2021, November 15, 2021, March 15, 2022, August 10, 2022, November 15, 2022, March 15, 2023, August 10, 2023, November 15, 2023

[PAR-20-310 \(R01\)](#) Clinical Trial Optional

Health Services Research on Minority Health and Health Disparities

The primary interest of this FOA is research on system-wide health services research that encompasses the diversity of individuals served within these health care systems. It is expected that projects will include patient or participant samples that are representative of the population served by the health care system(s) to be studied. Projects that include populations that identify across more than one health disparity group are encouraged.

Application Due Dates: November 17, 2021; March 17, 2022; November 17 2022; February 17, 2023.

[PAR-20-302\(R01\)](#)

[PAR-20-303 \(R21\)](#)

Tobacco Control Policies to Promote Health Equity

Specifically, this FOA aims to stimulate scientific inquiry focused on innovative state and local level tobacco prevention and control policies. The long-term goal of this FOA is to reduce disparities in tobacco-related cancers, and in doing so, to promote health equity among all populations.

Application Due Dates: [Standard dates](#) apply.

[PAR-20-289 \(R25\)](#)-Clinical Trial Not Allowed

NIAID Research Education Program

The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. The PD/PI should be an established investigator in the scientific area in which the application is targeted and capable of providing both administrative and scientific leadership to the development and implementation of the proposed program. The PD/PI will be expected to monitor and assess the program and submit all documents and reports as required. Participants are limited to the following individuals:

- Graduate/health professional (e.g., medical) students, medical residents, postdoctoral fellows, and/or early-career faculty. For this program "early career faculty" must be within the first 8 years of their first faculty appointment.
- Participants may be from a single career stage, or programs may propose to bridge several career stages of participants.
- Participants may be early career researchers that are moving into new research areas relevant to the NIAID research.

Note that high school and undergraduate students, postbaccalaureate fellows, and master's level graduate students may not be supported as participants under this FOA.

Application Due Dates: December 7, 2021; and December 7, 2022

[PAR-21-027 \(R01\)](#) Clinical Trial Not Allowed

Multidisciplinary Approaches to HIV-Associated Comorbidities and Prioritizing Intervention Targets

This FOA seeks applications for comprehensive systems biology studies using multidisciplinary team science to identify common, overlapping etiologies of HIV-associated comorbidities. Ultimately, the goal is to identify targets for intervention to mitigate multiple comorbidities associated with HIV infection.

Application Due Dates: May 7, 2021, January 7, 2022, May 7, 2022, January 7, 2023.

[PAR-21-044 \(X01\)](#)

Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access

This Funding Opportunity Announcement (FOA) allows investigators to apply for access to the Population Assessment of Tobacco and Health (PATH) Study biospecimens for use in conducting tobacco-related research studies. The PATH Study collects data from adults and youth. Investigators proposing meritorious and feasible studies consistent with PATH Study objectives and/or research priorities for tobacco regulatory science will be given highest priority for access to PATH Study biospecimens.

Application Due Dates: October 29, 2021, April 29, 2022, October 31, 2022, April 28, 2023, October 31, 2023.

[PAR-20-307\(P30\)](#) Clinical Trial Optional

[PAR-20-308\(P30\)](#) Clinical Trial Optional

Developmental AIDS Research Centers on Mental Health and HIV/AIDS

D-ARC awards permit the centralized coordination of affiliated research activities, foster the development of scientific innovations and new collaborations, encourage interdisciplinary research, and facilitate the dissemination of public health advances to implementing agencies, academia, affected communities, and policymakers. These Centers must have the potential to support research over a range of cross-cutting areas that may include biological, biomedical, behavioral, neuroscience, mental health, prevention, clinical sciences, and implementation science research.

Application Due Dates: August 25, 2021, August 25, 2022, and August 25, 2023.

[PAR-21-033](#) (R01 Clinical Trial Required)

National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis

The purpose of this FOA is to seek research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of the National Cancer Institute's (NCI) Division of Cancer Treatment and Diagnosis (DCTD) and the Office of HIV and AIDS Malignancies (OHAM, Office of the Director). Applicants are strongly encouraged to consult the NCI DCTD website and/or the OHAM website to learn more about the various program goals, research priorities, and strategies developed to fight cancer. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this FOA. This FOA does not accept phase III clinical trials in any area of cancer research;

Application Due Dates: Standard dates apply.

[PAR-21-035](#) (R01 Clinical Trial Required)

Cancer Prevention and Control Clinical Trials Grant Program

The National Cancer Institute (NCI) invites applications for support of investigator-initiated clinical trials related to the programmatic interests of the NCI Division of Cancer Prevention and/or the NCI Division of Cancer Control and Population Sciences that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this FOA and the application instructions.

Application Due Dates: Standard dates apply.

[PAR-21-038](#) (R01 Clinical Trial Not Allowed)

[PAR-21-039](#) (R01 Basic Experimental Studies with Humans Required)

Stephen I. Katz Early Stage Investigator Research Project Grant

The Stephen I. Katz Early Stage Investigator Research Project Grant supports an innovative project that represents a change in research direction for an early stage investigator (ESI) and for which no preliminary data exist. Applications submitted to this Funding Opportunity Announcement (FOA) must not include preliminary data. Applications must include a separate attachment describing the change in research

direction. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

Application Due Dates: May 26, 2021; September 28, 2021; January 26, 2022; May 26, 2022; September 27, 2022; January 26, 2023; May 26, 2023; September 26, 2023

[PAR-21-072](#) (R24 Clinical Trial Not Allowed)

NIAAA Resource-Related Research Projects

The purpose of the R24 grant is to support investigator-initiated resources designed to provide materials and services to support and advance biomedical research on a national basis. An R24 resource grant mechanism is a non-hypothesis-driven activity to provide data, materials, tools, or services that are essential to making timely, high quality, and cost-efficient progress in a field. Hypothesis-driven research applications should not be submitted in response to this program announcement but to another mechanism that encourages this type of research.

Application Due Dates: Standard dates apply.

[PAR-21-077](#) (R21/R33 - Clinical Trial Not Allowed)

Exploring the Scientific Value of Existing or New Sepsis Human Biospecimen Collections

This FOA invites applicants to submit proof of concept and scale-up studies to determine the scientific value of existing or new collections of human sepsis biospecimens with associated patient health record data. The biospecimens used in this study must be linked to clinical datasets useful for sepsis endotyping/stratification and characterization of disease trajectory, and the use of contemporary cutting-edge technologies in the analysis of these biospecimens is highly encouraged. The FOA will provide support for up to two years (R21 phase) for research planning activities and feasibility studies, followed by the possible transition to up to two additional years of scaled-up, expanded, or confirmatory research support (R33 phase).

Application Due Dates: Standard dates apply

[PAR-20-315](#) (R00 Clinical Trial Optional)

Limited Competition: Lasker Clinical Research Scholars Transition Award

The Lasker Clinical Research Scholars Program supports research activities during the early stage careers of independent clinical researchers. This FOA offers the opportunity for current Lasker awardees (Si2) to apply for the transition phase (R00) of the program. In the R00 phase, successful Si2 scholars will receive up to 5 years of NIH support for their research at an extramural research facility.

Application Due Dates: Rolling receipt dates

[PAR-21-022](#) (R01 Clinical Trial Optional)

[PAR-21-023](#) (R34 Clinical Trial Optional)

Multi-Site Studies for System-Level Implementation of Substance Use Prevention and Treatment Services

This FOA seeks research projects that will test implementation strategies intended to achieve system-wide integration of evidence-based practices (interventions, guidelines, or service delivery models) to prevent or treat substance use disorders (broadly defined to include alcohol, tobacco and other drugs, as well as prescription medications). Areas of interest also include implementation of guidelines related to the appropriate use of opioids for pain management in individuals with or at risk for opioid use disorder. When clearly justified, applicants may propose to test strategies that are designed to achieve system-wide de-implementation of programs or clinical practices that are ineffective, unproven, wasteful or harmful.

Application Due Dates: July 19, 2021; November 15, 2021; July 19, 2022; November 15, 2022; July 19, 2023; November 15, 2023.

[PAR-21-065](#) Curriculum or Methods Development (R25 Clinical Trial Not Allowed)

[PAR-21-066](#) Courses for Skills Development (R25 Clinical Trial Not Allowed)

[PAR-21-067](#) Research Experiences (R25 Clinical Trial Not Allowed)

Cancer Research Education Grants Program

The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause,

diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients.

Application Due Dates: Standard dates apply.

[PAR-21-080](#) (R01 Clinical trial not allowed)

[PAR-21-081](#) (R01 Clinical Trial Optional)

Addressing the Etiology of Health Disparities and Health Advantages Among Immigrant Populations

Addressing the Etiology of Health Disparities and Health Advantages Among Immigrant Populations

The purpose of this FOA is to support innovative research to understand factors uniquely associated with the immigration experience that contribute to health disparities or health advantages among U.S. immigrant populations. Most research on immigrant health does not consider the factors and processes that pushed migration of members from groups or subsets of groups from one country to another. Little attention has been given to integration of the pre-existing experiences, (for example, starvation resulting from rapid environmental changes, changing food sources, exposures to toxic chemicals and pesticides), and how the experience of migration itself, or how the process of adjustment and adaptation to a new cultural, social, political and ecological environment may affect health outcomes. It is also important to consider the period(s) in the life course when immigration was experienced and how that experience may affect health outcomes.

Application Due Dates: Standard dates apply.

[PAR-21-068](#) (R01 Clinical Trial Optional)

[PAR-21-069](#) (R21 Clinical Trial Optional)

Multidisciplinary Studies of HIV/AIDS and Aging

This FOA encourages applications at the intersection of HIV and aging by addressing two overarching objectives: 1) to improve understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) to improve approaches for testing, prevention, and treatment of HIV infection, and management of HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying our current understanding of aging science.

Application Due Dates: Standard dates apply.

[PAR-21-097](#) (R34 Clinical Trial Optional)

Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders

This FOA for R34 planning grant applications focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this FOA is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and incidence of FASD and (2) interventions for FASD. It is expected that research conducted via this mechanism will consist of studies that are a pre-requisite for preparing and submitting subsequent applications for larger scale FASD prevention or intervention studies.

Application Due Dates: June 17, 2021, October 19, 2021, February 17, 2022, June, 17, 2022, October 18, 2022, February 17, 2023, June 19, 2023, October 17, 2023

[PAR-21-098](#) (R61/R33 Clinical Trial Optional)

Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders

This FOA focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this FOA is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and the incidence of FASD and (2) interventions for FASD. These objectives will be accomplished with the Exploratory/Developmental Phased Award (R61/R33) mechanism, clinical trial optional. The R61 phase will support pilot studies or secondary data analysis for hypothesis development and feasibility, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R61 phase. Highest priority will be given to applications with clinical trials.

Application Due Dates: June 17, 2021, October 19, 2021, February 17, 2022, June, 17, 2022, October 18, 2022, February 17, 2023, June 19, 2023, October 17, 2023

[PAS-21-031](#) (R01 Clinical Trial Optional)

Priority HIV/AIDS Research within the Mission of the NIDDK

This Funding Opportunity Announcement (FOA) seeks to stimulate HIV/AIDS research within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) that align with the HIV/AIDS research priorities outlined by the NIH Office of AIDS Research (OAR). These priorities were most recently described in [NOT-OD-20-018 UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding](#).

Application Due Dates: Standard dates apply.

[PAR-21-170](#) (K01 Independent Basic Experimental Studies with Humans Required)

[PAR-21-171](#) (K01 Clinical Trial Required)

[PAR-21-172](#) (K01 Clinical Trial Not Allowed)

Transition to Independent Environmental Health Research (TIEHR) Career Award

The Transition to Independent Environmental Health (TIEHR) Career Award is a 3-year bridge scholar development program for newly independent faculty who intend to pursue research careers in environmental health sciences. At the conclusion of the career development period the candidates are expected to demonstrate they can successfully compete for research funding in the environmental health sciences.

Application Due Dates: Standard dates apply.

[PAR-21-173](#) (R16 - Clinical Trial Not Allowed)

Support for Research Excellence – First Independent Research (SuRE-First) Award

The purpose of SuRE-First awards is to support research grants for faculty investigators who have not had prior independent external research grants. Since the SuRE-First Award is structured to best support a single PD/PI, multiple PD(s)/PI(s) are not allowed. PD(s)/PI(s) with similar or complementary research interests may apply separately. A PD/PI must have a full-time tenure-track (or equivalent) faculty appointment at the applicant institution and be eligible to apply for NIH research project grants.

Application Due Dates: Standard dates apply.

[PAR-21-183](#) (UG3/UH3 Clinical Trial optional)

Developing Digital Therapeutics for Substance Use Disorders

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of Digital Therapeutics (DTx) to treat Substance Use Disorders (SUDs). The primary objective of this FOA is to move DTx to their next step in the development process, with the ultimate goal of generating new, FDA authorized, disseminated treatments for SUDs. Applications may focus on the pre-clinical and/or clinical development and testing of new DTx or existing DTx developed for other indications.

Open Date (Earliest Submission Date): July 04, 2021

Application Receipt Dates: Multiple dates, see announcement.

[PAR-21-206](#) (R01 Clinical Trial Optional)

Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes.

Open Date (Earliest Submission Date): May 05, 2021

Application Receipt Dates: Multiple dates, see announcement.

[PAR-21-208](#) (R21 Clinical Trial Optional)

Cutting-Edge Basic Research Awards (CEBRA)

The proposed research should: 1. develop, and/or adapt, revolutionary techniques or methods for addiction research or that show promising future applicability to SUD research; and /or 2. test an innovative and significant hypothesis for which there are scant precedent or preliminary data and which, if confirmed, would transform current thinking. The program supports high-risk and potentially high-impact research that is

underrepresented or not included in NIDA's current portfolio that has the potential to transform SUD research.

Open Date (Earliest Submission Date): July 10, 2021

Application Receipt Dates: Multiple dates, see announcement.

**[PAR-21-196](#) (R25 Independent Clinical Trial Not Allowed)
Innovative Programs to Enhance Research Training (IPERT)**

The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral, and clinical research needs. this FOA will support creative educational activities with a primary focus on: ***Courses for Skills Development; Mentoring Activities.***

Application Due Dates: October 14, 2021; October 14, 2022; October 13, 2023

[PAR-21-197](#) (UG3/UH3 Clinical Trial Required)

NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement

The purpose of this Funding Opportunity Announcement (FOA) is to encourage UG3/UH3 phased cooperative agreement research applications to plan and implement behavioral and social intervention clinical trials. Studies appropriate for this announcement include clinical trials to develop and test behavior change interventions related to dental, oral, or craniofacial conditions. Awards made under this FOA will initially support a milestone-driven planning phase (UG3) for up to 2 years, with possible transition to a clinical trial implementation phase (UH3) of up to five years.

Application Due Dates: Multiple dates, see announcement.

[PAR-21-207](#) (R01 Clinical Trial Optional)

Mechanism-Focused Research to Promote Adherence to Healthful Behaviors to Prevent Mild Cognitive Impairment (MCI) and Alzheimer's Disease and Related Dementias

This FOA invites R01 applications for ancillary studies that address psychological and interpersonal mechanisms driving adherence to behavior or lifestyle change relevant to the prevention of cognitive decline, Mild Cognitive Impairment (MCI), and Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This FOA will specifically support ancillary studies to ongoing, early- to late-stage clinical intervention trials.

Open Date (Earliest Submission Date): August 15, 2021

Application Due Dates: Multiple dates, see announcement.

[NIH Funding Opportunities: Program Announcements \(PA\)](#)

The following opportunities have standard due dates unless noted otherwise:

[PA-21-164](#)

Using Innovative Digital Healthcare Solutions to Improve Quality at the Point of Care (R21/R33 - Clinical Trial Optional)

Expiration Date: July 18, 2024

[PA-21-151](#)

NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)

Expiration Date: January 08, 2024

[PA-21-071](#)

Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)

Expiration Date: May 8, 2023

[PA-20-272](#)

Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

Expiration Date: July 24, 2023

[PA-21-047](#) Ruth L. Kirschstein National Research Service Award (NRSA) Individual Senior Fellowship (Parent F33)

[PA-21-048](#) Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32)

[PA-21-049](#) Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions with NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)

[PA-21-050](#) Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)

[PA-21-051](#) Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31)

[PA-21-052](#) Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (Parent F31-Diversity)

Expiration Date: September 8, 2023

[PA-21-110](#) Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clinical Trial Optional)

Expiration Date: May 08, 2024

Kudos to UB for being ranked No. 1 in the world in The Impact Rankings. Our climate actions are being recognized!!

<http://www.buffalo.edu/ubnow/stories/2021/04/the-impact-rankings.html>